The American Society of Plastic Surgeons (ASPS) has taken a decisive step away from the prevailing medical consensus on pediatric gender medicine, issuing new professional guidance urging that gender-related surgical procedures be deferred until patients reach at least 19 years old.
The move signals a significant shift by one of the nation’s largest surgical organizations and adds fresh momentum to ongoing scrutiny of medical interventions for minors with gender dysphoria.
In a newly released position statement, ASPS concluded that the existing scientific evidence supporting gender-related endocrine and surgical treatments for children and adolescents remains insufficient to justify irreversible medical intervention.
The group characterized the evidence base as “low quality/low certainty,” determining that it fails to establish a favorable balance between potential benefits and long-term risks.
ASPS cited a comprehensive federal review conducted by the Department of Health and Human Services (HHS), which examined available research and best practices related to pediatric gender dysphoria.
That review emphasized uncertainty surrounding long-term outcomes and raised ethical concerns about subjecting minors to permanent procedures amid unresolved questions about efficacy and harm.
Federal health officials praised the announcement, framing it as a corrective to what they describe as an era of aggressive medicalization.
HHS Secretary Robert F. Kennedy Jr. commended ASPS for “defending sound science,” while Deputy Secretary Jim O’Neill described the decision as a reaffirmation of biological reality.
Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz likened sex-rejecting procedures for minors to historical medical practices later abandoned after evidence proved inadequate.
Founded in 1931, ASPS represents more than 11,000 physician members and emphasized that its guidance does not constitute a binding clinical practice guideline, according to Stat News.
The organization stressed its opposition to criminal or punitive measures against physicians, arguing instead that evolving medical questions are best addressed through professional self-regulation rather than legislative enforcement.
The statement highlighted research indicating that a large majority of children diagnosed with gender dysphoria experience resolution without medical intervention.
Among adolescents, ASPS noted that existing evidence suggests many also remit over time.
These findings, the group argued, heighten ethical concerns surrounding irreversible procedures performed during periods of psychological and developmental fluidity.
ASPS further underscored that while patient autonomy is an important principle, it does not absolve clinicians of their obligation to safeguard long-term health.
Surgeons, the organization stated, retain independent responsibility for determining whether a minor can fully comprehend the permanent consequences of surgery.
Heightened caution, robust documentation, and clear disclosure of uncertainty were advised when considering irreversible interventions.
The guidance reflects years of internal review, reinforced by international evidence assessments, including the United Kingdom’s Cass Review, which similarly questioned the quality and reliability of existing studies.
Former ASPS President Scot Bradley Glasberg said the timing of the announcement during President Donald Trump’s administration was coincidental and not directed by federal officials, describing the shift as the culmination of an evolving evidence evaluation process.
The move places ASPS at odds with organizations such as the American Academy of Pediatrics and the American Medical Association (AMA), which continue to support certain forms of gender-related care for minors.
However, the AMA has acknowledged that evidence supporting surgical intervention for adolescents is insufficient and agrees such procedures should generally be postponed until adulthood, according to National News.
Commentators at City Journal described the decision as a major escalation, noting that ASPS is the first major U.S. medical association to explicitly disavow gender-transition surgeries for minors.
The statement also raised concerns about puberty blockers and cross-sex hormones, citing unresolved questions about long-term effects and warning against using autonomy arguments to justify treatments lacking a demonstrated risk-benefit advantage.
Federal officials say the announcement reflects a broader reevaluation of pediatric gender medicine across hospital systems and provider networks, with potential implications for national medical standards moving forward.
